Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
| 0.3462 Delayed Data As of Jun 08 |  -0.0138 / -3.83%Today’s Change | 0.30 Today|||52-Week Range 1.60 | -34.68% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $17.8M |
Company Description
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Contact Information
Zynerba Pharmaceuticals, Inc. 80 West Lancaster Avenue Devon Pennsylvania 19333 |
Employees
Shareholders
| Individual stakeholders | 7.36% |
| Mutual fund holders | 7.06% |
| Other institutional | 5.06% |
Top Executives
| Armando Anido | Chairman & Chief Executive Officer |
| Terri B. Sebree | President |
| James E. Fickenscher | Chief Financial Officer & VP-Corporate Development |
| Nancy Tich | Vice President-Clinical |
| Stephen O'Quinn | Vice President-Medical Affairs |
